Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors Article

Rolfo, Christian, Giovannetti, Elisa, Hong, David S et al. (2014). Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors . CANCER TREATMENT REVIEWS, 40(8), 990-1004. 10.1016/j.ctrv.2014.05.009

Open Access International Collaboration

cited authors

  • Rolfo, Christian; Giovannetti, Elisa; Hong, David S; Bivona, T; Raez, Luis E; Bronte, Giuseppe; Buffoni, Lucio; Reguart, Noemi; Santos, Edgardo S; Germonpre, Paul; Taron, Miguel; Passiglia, Francesco; Van Meerbeeck, Jan P; Russo, Antonio; Peeters, Marc; Gil-Bazo, Ignacio; Pauwels, Patrick; Rosell, Rafael

sustainable development goals

authors

publication date

  • September 1, 2014

published in

keywords

  • ACQUIRED-RESISTANCE
  • AFATINIB BIBW 2992
  • CELL LUNG-CANCER
  • EGFR mutations
  • GROWTH-FACTOR-RECEPTOR
  • Life Sciences & Biomedicine
  • MESSENGER-RNA EXPRESSION
  • NSCLC
  • New drugs
  • Novel therapeutic strategies
  • OPEN-LABEL
  • Oncology
  • PREVIOUSLY TREATED PATIENTS
  • RANDOMIZED PHASE-II
  • Science & Technology
  • T790M MUTATION
  • TKI inhibitors resistance
  • TYROSINE KINASE INHIBITORS

Digital Object Identifier (DOI)

publisher

  • ELSEVIER SCI LTD

start page

  • 990

end page

  • 1004

volume

  • 40

issue

  • 8